June 2007
Worldwide Biotech;Jun2007, Vol. 19 Issue 6, p3
Trade Publication
The article reports that Neuromed Pharmaceuticals Ltd. has licensed from ALZA Corp. the exclusive U.S. rights to develop and commercialize OROS Hydromorphone. Neuromed is a biopharmaceutical firm developing the next-generation chronic pain drugs. Hydromorphone is an extended release formulation of a potent opioid analgesics in Phase 3 clinical development. Information on the terms of the licensing agreement between Neuromed and ALZA is presented


Related Articles

  • Neuromed Licenses ALZA Pain Drug For $30M.  // Bioworld Week;4/30/2007, Vol. 15 Issue 18, p3 

    The article reports on the payment of Neuromed Pharmaceuticals Ltd. to Johnson & Johnson subsidiary ALZA Corp. in exchange for U.S. rights to OROS Hydromorphone, a pain drug. The said drug is a latestage, specialty pharmaceutical product in need of regulatory and marketing support. Moreover,...

  • Neuromed Licenses Late-Stage Pain Drug From ALZA For $30M. Morrison, Trista // BioWorld Today;4/25/2007, Vol. 18 Issue 80, p1 

    The article discusses the decision of Neuromed Pharmaceuticals to pay ALZA Corp. $30 million in exchange for the U.S. rights to the pain drug OROS Hydromorphone. The author reveals that the pain drug is in need of regulatory and marketing support. According to Neuromed president and chief...

  • OTHER NEWS TO NOTE.  // BioWorld Today;12/12/2007, Vol. 18 Issue 240, p3 

    This section offers news briefs related to the pharmaceutical industry. Anavex Life Sciences Corp. said that the preclinical data of its colorectal drug candidate ANAVEX 7-1037 can kill human HCT116 colon cancer cells. Anesiva Inc. and Medical Futures Inc. announced an agreement granting an...

  • Neuromed Raises $53.3M To Push Its Pain Program.  // Bioworld Week;8/27/2007, Vol. 15 Issue 35, p3 

    The article reports that Neuromed Pharmaceuticals Ltd. raised $53.3 million in the U.S. The fund was raised through private financing and brought the company's running total of venture capital to more than $126 million. It was dedicated in the development of an opioid painkiller. The company's...

  • Furiex Pharmaceuticals Announces Closing of Priligy(r) Asset Transfer and License Agreements.  // Biomedical Market Newsletter;8/7/2012, Vol. 21, p1 

    The article focuses on the closing of Asset Transfer Agreement with ALZA Corp. and Janssen Pharmaceutica and the license agreement with the company Menarini Group by Furiex Pharmaceuticals Inc. for the commercialization and product rights of Priligy. It informs that Priligy is the first oral...

  • BioDelivery and Endo Health initiate Phase III chronic pain study.  // PharmaWatch: CNS;Sep2012, Vol. 11 Issue 9, p14 

    The article reports on the initiation of the Phase III clinical program for BEMA Buprenorphine for the treatment of moderate to severe chronic pain by BioDelivery Sciences International Inc. (BDSI) and Endo Health Solutions Inc. Two efficacy studies will comprise the program, one in opioid naive...

  • A partnership between patient and case manager.  // Patient Education Management;Aug2007, Vol. 14 Issue 8, p92 

    The article focuses on the importance of partnership between the patient and case manager in chronic pain management according to Dennis C. Turk, professor of anesthesiology and pain research at the University of Washington in Seattle.

  • SIGN: chronic pain.  // Pulse;Jan2014, p16 

    The article presents guidelines for general practitioners (GPs) for the management of chronic pain, issued by the Scottish Intercollegiate Guidelines Network (SIGN).

  • TIPS for Coping With Chronic Pain.  // Neurology Reviews;Oct2006, Vol. 14 Issue 10, p27 

    The article offers tips on how to cope with chronic pain.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics